Literature DB >> 10939715

Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

H Chikazawa1, K Nishiya, A Matsumori, K Hashimoto.   

Abstract

To investigate the prevalence and clinical relevance of immunoglobulin (Ig) isotypes of antimyeloperoxidase (MPO) and antilactoferrin (LF) antibodies in collagen diseases, enzyme-linked immunosorbent assay was employed to detect the Ig isotypes of both antibodies. The purified proteins of MPO and LF were used as two major representative antigens for anti-neutrophil cytoplasmic antibodies (ANCA) with a perinuclear staining pattern by an indirect immunofluorescent technique. We examined 131 serum samples from 79 patients with rheumatoid arthritis (RA), 32 with systemic lupus erythematosus (SLE), 14 with progressive systemic sclerosis (PSS), 6 with polymyositis/dermatomyositis (PM/DM), and 5 with idiopathic crescentic glomerulonephritis who served as positive controls and 36 healthy subjects who served as controls. A limited number of patients with RA (4-10%), SLE (6-9%), and PSS (7-14%) but not PM/DM showed positive IgG or IgA anti-MPO antibody (MPO-ANCA) but not IgM MPO-ANCA. However, 10-20% of RA, 40-60% of SLE, 20-36% of PSS but none of the PM/DM patients showed positive IgG, IgA, or IgM anti-LF antibody (LF-ANCA). MPO- and LF-ANCA positivity in RA patients was correlated with markers of disease activity such as the erythrocyte sedimentation rate, C-reactive protein, and serum Ig levels. IgG LF-ANCA but not MPO-ANCA positivity in SLE patients also was correlated with the disease activity index but not with clinical features. Neither MPO- nor LF-ANCA positivity in PSS patients was correlated with any clinical features. Overall, both MPO- and LF-ANCA were found mainly in RA, SLE, and PSS patients but not in PM/DM patients. The Ig isotypes of MPO- and LF-ANCA frequently belonged to both IgG and IgA and rarely to the IgM class. Both MPO- and LF-ANCA positivity reflected disease activity in RA and SLE rather than specific organ involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939715     DOI: 10.1023/a:1006667703202

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  31 in total

1.  Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  N Pourmand; M Wahren-Herlenius; I Gunnarsson; E Svenungsson; B Löfström; Y Ioannou; D A Isenberg; C G Magnusson
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; P C Limburg; M van der Giessen; M G Huitema; M I Koolen; R J Hené; T H The; G K van der Hem
Journal:  Arthritis Rheum       Date:  1990-08

3.  Autoantibodies to myeloperoxidase in systemic sclerosis.

Authors:  I C Locke; J G Worrall; B Leaker; C M Black; G Cambridge
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

4.  A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants.

Authors:  K Tomizawa; E Mine; A Fujii; Y Y Ohashi; S Yamagoe; Y Hashimoto; A Ishida-Okawara; M Ito; M Tanokura; T Yamamoto; Y Arimura; T Nagasawa; S Mizuno; K Suzuki
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

5.  IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications.

Authors:  C Jorgensen; M C Legouffe; C Bologna; J Brochier; J Sany
Journal:  Clin Exp Rheumatol       Date:  1996 May-Jun       Impact factor: 4.473

6.  Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis.

Authors:  I E Coremans; E C Hagen; M R Daha; F J van der Woude; E A van der Voort; C Kleijburg-van der Keur; F C Breedveld
Journal:  Arthritis Rheum       Date:  1992-12

7.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

8.  Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE.

Authors:  M Galeazzi; G Morozzi; G D Sebastiani; F Bellisai; R Marcolongo; R Cervera; E De Ramòn Garrido; A Fernandez-Nebro; F Houssiau; A Jedryka-Goral; A Mathieu; C Papasteriades; J C Piette; R Scorza; J Smolen
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

9.  Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis.

Authors:  H Endo; T Hosono; H Kondo
Journal:  J Rheumatol       Date:  1994-05       Impact factor: 4.666

10.  Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis.

Authors:  S Akimoto; O Ishikawa; T Tamura; Y Miyachi
Journal:  Br J Dermatol       Date:  1996-03       Impact factor: 9.302

View more
  9 in total

1.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

2.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

3.  Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells.

Authors:  Hans U Lutz
Journal:  Transfus Med Hemother       Date:  2012-08-27       Impact factor: 3.747

Review 4.  Myeloperoxidase-antineutrophil cytoplasmic antibody-related crescentic glomerulonephritis after treatment for clinically amyopathic dermatomyositis: a coincidental combination or not?

Authors:  Hirohisa Kawai; Wataru Kitagawa; Natsuko Suzuki; Kunihiro Maeda; Keisuke Suzuki; Naoto Miura; Hiroyuki Morita; Syogo Banno; Masahiro Yamamura; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

5.  Overlap between dermatomyositis and ANCA vasculitides.

Authors:  Claudia Yuste; Molefe Rapalai; Benjamin A Pritchard; Terence J Jones; Constanza Amoasii; Atheer Al-Ansari; Satish B Ramakrishna
Journal:  Clin Kidney J       Date:  2013-12-23

Review 6.  Mechanisms tagging senescent red blood cells for clearance in healthy humans.

Authors:  Hans U Lutz; Anna Bogdanova
Journal:  Front Physiol       Date:  2013-12-25       Impact factor: 4.566

7.  The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation.

Authors:  Haruki Shida; Daigo Nakazawa; Yu Tateyama; Arina Miyoshi; Yoshihiro Kusunoki; Fumihiko Hattanda; Sakiko Masuda; Utano Tomaru; Tamihiro Kawakami; Tatsuya Atsumi; Akihiro Ishizu
Journal:  Front Immunol       Date:  2016-12-23       Impact factor: 7.561

Review 8.  The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.

Authors:  Sabina Janciauskiene; Sabine Wrenger; Stephan Immenschuh; Beata Olejnicka; Timm Greulich; Tobias Welte; Joanna Chorostowska-Wynimko
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

9.  A Novel Murine Anti-Lactoferrin Monoclonal Antibody Activates Human Polymorphonuclear Leukocytes through Membrane-Bound Lactoferrin and TLR4.

Authors:  Xiao-Min Hu; Yan-Rui Xu; Ru Yan; Shu-Liang Sun; Hong-Liang Dong; Jun Wang; Xiao-Ming Gao
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.